Clostridium Difficile Clinical Trial
Official title:
Efficacy and Safety of the Probiotic Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile Related Infections in Hospitalized Adult Patients
The purpose of this study is to find whether Lactobacillus reuteri prevents antibiotic-associated diarrhea and related Clostridium difficile infections. Subjects will be admitted from the University Hospitals Case Medical Center. They will be randomly assigned to an intervention group receiving L. reuteri or a placebo. Supplementation will occur during antibiotic treatment and for an additional 7 days after cessation of treatment. Data collection will occur at baseline, end of antibiotic use, 7 days after antibiotic cessation, and 21 days after antibiotic cessation. Primary data includes diarrhea instances. Secondary data includes severity of diarrhea, presence of C. difficile toxins, and presence of other GI symptoms.
The data being measured for this study include:
Primary outcome = incidence of diarrhea during and after treatment with antibiotics. An
episode of diarrhea is defined as the discrete period between the time when stool output
meets or exceeds three soft and unformed or watery bowel movements to the time when formed
stools return, which must be at least 48 hours later.
Secondary variables:
1. severity of diarrhea measured as the discrete period between the time when stool output
meets or exceeds 3 soft and unformed or watery bowel movements to the time when formed
stools return.
2. frequency of stool samples positive for C. Difficile toxin A or B at baseline, when
presenting with diarrhea during the study period, and at the follow-up 21 days
post-antibiotic-treatment to detect possible clearance of C. Difficile, in patients
ingesting L. reuteri versus placebo.
3. frequencies of other gastrointestinal symptoms at 1, 2, and 4 weeks, in the L. reuteri
group versus placebo and assessed by the validated Gastrointestinal Symptom Rating
Score.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02896244 -
AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment
|
||
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Recruiting |
NCT01973465 -
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
|
N/A | |
Terminated |
NCT01048567 -
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
|
Phase 2 | |
Completed |
NCT01066221 -
Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile
|
N/A | |
Not yet recruiting |
NCT03586206 -
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
|
||
Completed |
NCT02563106 -
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
|
Phase 2 | |
Completed |
NCT02207140 -
Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly
|
Phase 0 | |
Completed |
NCT02857582 -
Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile
|
Phase 2 | |
Not yet recruiting |
NCT01942447 -
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
|
N/A | |
Active, not recruiting |
NCT01703494 -
Fecal Transplant for Relapsing C. Difficile Infection
|
Phase 2 | |
Completed |
NCT01813500 -
Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients
|
N/A | |
Completed |
NCT01087892 -
Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection
|
N/A | |
Suspended |
NCT00591357 -
Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy
|
Phase 4 | |
Recruiting |
NCT00377078 -
Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.
|
N/A | |
Completed |
NCT02254967 -
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
|
Phase 4 | |
Terminated |
NCT01775397 -
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
|
Phase 4 | |
Terminated |
NCT03617172 -
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
|
Phase 2 | |
Recruiting |
NCT05622721 -
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
|
||
Completed |
NCT02437487 -
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
|
Phase 2 |